Development of Adverse Outcome Pathway for PPARγ Antagonism Leading to Pulmonary Fibrosis and Chemical Selection for Its Validation: ToxCast Database and a Deep Learning Artificial Neural Network Model-Based Approach

AOP for PPARγ inactivation leading to fibrosis. MIE is an inactivation

Frontiers From Causal Networks to Adverse Outcome Pathways: A Developmental Neurotoxicity Case Study

Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity

Toxics, Free Full-Text

DDAC induces inflammation and fibroproliferation in the lungs. Mice

Frontiers A Case Study on Integrating a New Key Event Into an Existing Adverse Outcome Pathway on Oxidative DNA Damage: Challenges and Approaches in a Data-Rich Area

PDF) Novel QSAR Models for Molecular Initiating Event Modeling in Two Intersecting Adverse Outcome Pathways Based Pulmonary Fibrosis Prediction for Biocidal Mixtures

Defining Molecular Initiating Events in the Adverse Outcome Pathway Framework for Risk Assessment

PPARγ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis